Picking a PI in MM: Asking & Answering the W5 – Twitter Chat




Once considered an inevitable death sentence within a matter of months, multiple myeloma (MM) can now, in many cases, be transformed into a long-term chronic illness that can often be managed for decades. Recent advances in genomics and gene sequencing have led to a better understanding of the myeloma microenvironment in the pathophysiology of MM, which has in turn yielded new therapies that target the diseases through immunomodulatory, cellular, and genetic pathways. Proteasome inhibitors (PIs), specifically, are used across the continuum of care, and have become the backbone of treatment combinations in the relapsed/refractory MM (RRMM) setting, particularly in high-risk disease. However, there is no one standard of care for this disease, due to its complex and nuanced nature. This activity is designed to highlight optimal treatment combinations for standardized case study patients based on a wide variety of patient variabilities, including cytogenetic abnormalities, stage and age at diagnosis, whether and when autologous stem cell transplant (ASCT) might be performed, and multiple other prognostic factors.


Joseph Mikhael, MD, MEd, FRCPC, FACP
Professor, Applied Cancer Research and Drug Discovery
Translational Genomics Research Institute
City of Hope Cancer Center
Chief Medical Officer
International Myeloma Foundation
Phoenix, Arizona


Release date: April 22, 2020
Expiration date: April 22, 2021
Estimated time to complete activity: 1.0 hour(s)



This educational activity is intended for specialists in hematology (hematologists/oncologists), oncology (medical and radiation oncologists), and physician assistants and nurse practitioners who manage patients with MM.


Upon completion of this educational activity, participants will be able to:

  • Employ patient-focused strategies to improve outcomes among patients with multiple myeloma
  • Assess disparities in the treatment of multiple myeloma
  • Compare frailty indexes, scores and scales when evaluating patients with multiple myeloma

There are no fees for participating and receiving CME credit for this activity. During the period of April 22, 2020 through April 22, 2021, participants must:

  • Read the learning objectives and faculty disclosures
  • Complete the pretest
  • Study the educational activity
  • Complete the posttest and the evaluation form

A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest with a score of 100%.




Integrity Continuing Education, Inc. is accredited with commendation by the Accreditation Council for Continuing Medical Education to provide continuing medical education (CME) for physicians.


Live Participation on April 22, 2020:
Integrity Continuing Education, Inc. designates this live program for a maximum of 1.0 AMA PRA Category 1 Credit. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Participation from April 23, 2020 – April 22, 2021:
Integrity Continuing Education, Inc. designates this internet enduring material for a maximum of 1.0 AMA PRA Category 1 Credit. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


For information about ACCME accreditation of this activity, please contact Integrity Continuing Education, Inc. at (855) 835-4004 or info@integrityce.com.


Integrity Continuing Education, Inc. requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Integrity Continuing Education, Inc. for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The following faculty/planners reported the financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of these CME activities:

Joseph Mikhael, MD, Med, FRCPC, FACP
Consulting Fees: Amgen; Celgene; Karyopharm; Janssen; Sanofi; Takeda

The Integrity Continuing Education, Inc. planners/managers have nothing to disclose.


This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc. does not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


When you participate in an online educational activity sponsored by Integrity Continuing Education, Inc., you will be asked for your name, degree(s), affiliation(s), street address, telephone number, fax number, and…(continued)


Windows 98, 2000, XP, 2003, Vista, and 7
Internet Explorer 6/7
Firefox 2
Mozilla 1.7 or higher
Netscape 8.1 or higher
Flash Player 10

Mac OS X 10.3, 10.4
Safari 1.3 (Mac OS 10.3)
Safari 2.0 or higher (Mac OS 10.4)
Firefox 2
Flash Player 10
Use of Internet Explorer browser is not recommended.

Click here for more information on minimum system requirements.


The information provided at this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.


Provided by Integrity Continuing Education, Inc.


Supported by an educational grant from Takeda Oncology.

Continue to Pretest